Mitsubishi Paper Mills produces and develops not only printing paper, printing plate materials and printing systems supporting offset and other printing, but also supplies the media for almost all recording formats, such as pressure-sensitive, thermal, magnetic, electrographic, silver halide photography and inkjet paper. Furthermore, they are adding functional materials such as highly functional filters to their operating business, and they are increasing emphasis on research and development in new business areas.

OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.

Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. The firm involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

XY LLC develops sex selection technologies for non-human mammals. The company is headquartered in Navasota, TX.

Nippon Sanso KK is a private company headquartered in Japan, with operations in CN. The firm supplies industrial gases such as oxygen, nitrogen and argon; manufactures air separation plants, space simulation chambers and equipment related to liquid helium; supplies synthetic air; supplies LP gas; manufactures stainless steel vacuum bottles.\n.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Yinfeng Bioengineering Group Co., Ltd., established on 2011-04-19, Business scope includes general items:R&D and application of cell technology;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;Health Consulting Services(Does not include medical services);Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Daily necessities sales;Maternal and baby products sales;Cosmetics Wholesale;Cosmetics Retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Health food sales;Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Asymptote Ltd., specialists in cryochain technology for sensitive cellular therapies. Asymptote’s integrated suite of cryochain hardware, software and consumables are designed to maintain the potency of cellular therapies enabling ultra-low temperature freezing during production, all the way to thawing at the clinic prior to administering to patients.

Nipro Corp. engages in the manufacture and sale of medical equipment, pharmaceutical products, and glass products. Its operations are carried out through the following segments: Medical related, Pharmaceutical related, Pharma Packaging, and Others. The Medical related segment provides injection and infusion-related products, artificial organ-related products, functional products, and dialysis and diabetes-related products. The Pharmaceutical related segment involves the manufacture and sale of injections, oral agents, and pharmaceutical kit products. The Pharma Packaging segment provides glass products for bottle tubes, ampoules, thermos-use, and lighting. The Others segment includes real estate leasing. The company was founded on July 8, 1954 and is headquartered in Osaka, Japan.

Haier Biosciences comprehensively promotes the integration and innovation of IoT technology and low-temperature storage technology. Traditional storage devices are upgraded to IoT scenarios to meet the iterative needs of users such as clinical blood use, vaccination, and biobank applications, and build an IoT technology ecosystem. The blood network scenario program is based on the "Cloud Wing" Internet of Things blood cold storage box network device, which links blood collection, blood delivery and clinical blood use scenarios to achieve the full traceability of blood information from "blood donor" to "blood user". The vaccine network scenario plan is based on the "Haile Miao" vaccination box network device, linking the vaccination entrance and exit scenes, realizing the traceability of the last mile of vaccination, and the transparent and visible matching of the vaccine to ensure the safety of the vaccine. Vaccine Network has launched more than 500 vaccination sites across the country, and will build the country’s first fully-covered smart city vaccine network in Shenzhen, and enter 78 countries and regions including participating countries of the “Belt and Road”. 120,000 Internet of Things vaccination box-net devices have protected the health of 200 million children worldwide. The biological sample network scenario plan is based on the "cloud core" IoT ultra-low temperature storage box network device, which links sample collection, storage, and application scenarios to achieve cloud-network collaboration, accurate sample positioning, one-click access, and information traceability to promote samples Management change.

CryoLife, is a biological medical device company, which has been focused on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular reconstruction for patients for all ages. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using its SynerGraft technology. CryoLife's medical devices consist primarily of surgical adhesives, sealants, and hemostats, including BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), PerClot and HemoStase. In October of 2010, the Company began distributing PerClot for Starch Medical, Inc. (SMI). In May 2011, it acquired Cardiogenesis Corporation.

Develops and manufactures agricultural and noncrop products

Organ Recovery Systems, Inc. provides and transplantation technologies. Its products include LifePort sterile disposables, cargo carte, kidney perfusion solution, data station, battery cap, power cord, data cable, insulating cover and ice containers. The company was founded by David Kravitz in 1998 and is headquartered in Chicago, IL.

Lifeline Scientific, Inc., a medical technology company, develops products and services for cell, tissue, and organ transplantation in the United States and internationally. It offers LifePort Kidney Transporter, a medical device that provides kidney preservation, evaluation, and transport prior to transplantation; and LifePort Liver Transporter, a device used in liver transplantation. The company also provides Vasosol, a machine perfusion solution; Universal SealRing Cannula, which allows the use of organs with limited vascular access; LifePort Kidney Transporter rolling Cover that provides protection and manoeuvrability for LifePort Kidney Transporter while in transit; and LifePort WorkStation, which accommodates a range of medical solutions and additive gases.

Qingdao Haier Biomedical Technology Co., Ltd., established on 2016-12-19, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Refrigeration,Air Conditioning Equipment Sales;Manufacturing of experimental analysis instruments;Experimental analysis instrument sales;Instrument sales;Special Equipment Sales;Medical Research and Experimental Development;Internet of things technology research and development;IoT application service;IoT Device Sales;software development;software sales;Information system integration service;Sales of electrical machinery and equipment;Industrial automatic control system device manufacturing;Industrial automatic control system device sales;Sales of power electronic components;Sales of electronic measuring instruments;Sales of electronic special equipment;Auto New Car Sales;Metal Products Sales;Car rental;Machinery and Equipment Leasing;Special equipment rental;Research and Development of Household Appliances;Home Appliance Sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Professional cleaning,to clean,Disinfection service;Information Technology Consulting Services;Low temperature storage(Does not contain hazardous chemicals and other items that require approval);Office Equipment Sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of sterile equipment;Disinfection equipment sales;Drug Wholesale;road freight transport(Does not contain dangerous goods);Construction engineering design;Various construction activities;Import and export;Drug import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Stratatech Corporation, a regenerative medicine company, engages in the development and commercialization of cell-based and tissue-engineered skin substitute products for therapeutic and research applications. The company specializes in human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. Its products include StrataGraft skin tissue, a temporary wound cover that promotes wound healing by the patient's own cells and improve the wound bed to receive autografts; and ExpressGraft skin tissue, a genetically enhanced tissue that produces various levels of natural wound healing and antimicrobial factors. The company was founded in 2000 and is based in Madison, Wisconsin.